Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill form of Weight-Loss drug could offer same benefits as capsules

NCT ID NCT06440980

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether orforglipron, an experimental oral drug for weight management, works the same when given as a tablet versus a capsule. Healthy adults with a BMI between 27 and 40 take the drug for about 22 to 25 weeks, and researchers measure how much of the drug enters the bloodstream and how quickly the body clears it. The goal is to see if the tablet form can be used instead of capsules without changing the drug's effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
orforglipron (LY3502970), an oral drug
What this could lead to
If successful, this study could confirm that orforglipron tablets work the same as capsules, potentially leading to a more convenient treatment option for weight management.
What could go wrong
This is an early-phase trial focused on drug absorption, not weight loss. The results may not predict long-term effectiveness or safety, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

533 people

The number who actually took part.

Started

Jun 2024

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who are overtly healthy as determined by medical history and physical examination. * Have a stable body weight for one month prior to screening (less than or equal to 5 percent body weight gain or loss) and Body Mass Index (BMI) in range of 27 to 40 kilogram per meter square (kg/m²). * Participants must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures. * Have venous access sufficient to allow for blood sampling. Exclusion Criteria: * Have hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater. * Have a history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or other significant active, uncontrolled medical conditions. * Have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years. * Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome. * Have known clinically significant gastric emptying abnormality. * Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass) * Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer. * Have an abnormal 12-lead electrocardiogram (ECG) at screening. * Have history of pancreatitis. * Judged by the study investigator to be at serious suicidal risk and have answered "Yes" to either question 4 or 5 on the Columbia-Suicide Severity Rating Scale \[C-SSRS\]). * Have difficulty swallowing capsules or tablets.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy OBESE Obesity Overweight

Contacts and locations

Locations

  • Altasciences Company Inc.

    Overland Park, Kansas, 66212, United States

  • Anaheim Clinical Trials, LLC

    Anaheim, California, 92801, United States

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California, 90720, United States

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida, 32117, United States

  • Fortrea Clinical Research Unit

    Dallas, Texas, 75247, United States

  • Fortrea Clinical Research Unit

    Madison, Wisconsin, 53704, United States

  • QPS

    Springfield, Missouri, 65802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.